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Polymorphism in Microsomal Triglyceride Transfer
Protein: A Link Between Liver Disease and
Atherogenic Postprandial Lipid Profile in NASH?
Roberto Gambino,1 Maurizio Cassader,1 Gianfranco Pagano,1 Marilena Durazzo,1 and Giovanni Musso2
Nonalcoholic fatty liver disease (NAFLD) is emerging as an independent cardiovascular risk
factor, but mechanism(s) linking fatty liver to atherosclerosis are unknown. Microsomal
triglyceride transfer protein (MTP) 493 G/T polymorphism modulates circulating lipid
and lipoprotein levels in different subsets and has been linked to NAFLD. The impact of
MTP 493 G/T polymorphism, adipokines, and diet on postprandial lipoprotein profile
and liver disease was assessed in nonalcoholic steatohepatitis (NASH). Plasma lipids, tri-
glyceride-rich lipoprotein subfractions, high-density lipoprotein-C (HDL-C), and oxidized
low-density lipoprotein (LDL) after an oral fat loadwere cross-sectionally correlated toMTP
493 G/T polymorphism, dietary habits, adipokines, and liver histology in 29 nonobese
nondiabetic patients with NASH and 27 healthy controls. The severity of liver histology, the
magnitude of triglycerides (Tg), free fatty acid (FFA), and LDL-conjugated diene responses,
and the fall in HDL-C and apoA1 were significantly higher in NASH G/G (66% of patients)
than in the other genotypes, despite similar adipokine profile and degree of insulin resis-
tance. Postprandial large intestinal very-low-density lipoprotein (VLDL) subfraction A in-
creases independently predicted Tg (  0.48; P  .008), FFA (  0.47; P  0.010),
HDL-C ( 0.42;P 0.009), and LDL-conjugated diene ( 0.52;P 0.002) responses.
VLDL A apoB48 response was independently associated with liver steatosis (OR: 2.4; CI
1.7-9.6; P  0.031). Postprandial LDL-conjugated diene response predicted severe necro-
inflammation (OR: 3.3; CI 1.4-9.7;P 0.016) and fibrosis (OR: 2.8; CI 1.0-8,5;P 0.030);
postprandial apoA1 fall predicts severe fibrosis (OR: 2.1; CI: 1.5-6.1; P  0.015). Conclu-
sion:MTP -493 G/T polymorphismmay impact NASH bymodulating postprandial lipemia
and lipoproteinmetabolism; homozygous GG carriers have amore atherogenic postprandial
lipid profile than the other genotypes, independently of adipokines and insulin resistance.
(HEPATOLOGY 2007;45:1097-1107.)
Nonalcoholic fatty liver disease (NAFLD), themost common chronic liver disease in Westernpopulations, has been associated with insulin
resistance and metabolic syndrome.1,2 This association
prompted research on NAFLD as a cardiovascular risk
factor. Surrogate markers of NAFLD predicted incident
cardiovascular disease independently of classical risk fac-
tors, insulin resistance, and metabolic syndrome, in sev-
eral large prospective cohort studies.3,4 Furthermore, liver
histology independently correlated with carotid intima-
media thickness inNAFLD, suggesting the vessel wall and
the liver of these patients share common inflammatory
mediators.5 Mechanism(s) underlying this association are
unknown, nor is it known which subjects with nonalco-
holic steatohepatitis (NASH) are at greater cardiovascular
risk and should therefore be candidates for early aggressive
interventions.
The postprandial phase has been linked to atheroscle-
rosis and increased oxidative stress in diabetes.6 Increased
lipid peroxidation may have a role in the pathogenesis of
NASH, alone or in association with insulin resistance and
impaired adipokine signaling.1 The liver takes up circu-
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lating free fatty acid (FFA) in a dose-dependent fashion,
and low-density lipoprotein (LDL) and remnants
through the LDL-receptor and the liver-related receptor
protein. Consistently, postprandial lipid storage contrib-
utes substantially to the liver triglyceride (Tg) pool in
NAFLD7 and the magnitude of postprandial lipemia pre-
dicts liver steatosis.8,9
The functional polymorphism493 G/T in the micro-
somal triglyceride transfer protein (MTP) gene promoter has
been linked to liver disease in NAFLD: GG homozygosity,
or carrying a lower MTP activity than the other genotypes,
predicted more severe liver histology.10
This polymorphism modulates lipid and lipoprotein
levels in healthy and hypercholesterolemic subjects,11,12
but its impact on postprandial lipid metabolism in fatty
liver, as well as its interaction with other factors (insulin
resistance, adiposity, adipokines, oxidative stress, dietary
habits) in the pathogenesis of NASH, are unknown.
The impact of the493 G/T MTP polymorphism on
postprandial plasma lipid metabolism in nonobese non-
diabetic patients with NASH and healthy controls and
the interaction of this polymorphism with insulin resis-
tance, dietary habits, adipokines, and oxidative stress in
determining the severity of liver disease in NASH were
assessed.
Patients and Methods
Patient Selection. Twenty-nine patients were se-
lected (Table 1) according to the following criteria: per-
sistently (6 months) elevated liver enzymes;
ultrasonographic presence of bright liver without any
other liver or biliary tract disease. Exclusion criteria were:
a history of alcohol consumption40 g/week, as assessed
by a detailed interview extended to family members and
by a validated questionnaire filled in daily for 1 week by
the patients; a body mass index 30 kg/m2; positive
markers of viral, autoimmune, or celiac disease; abnormal
copper metabolism, thyroid function or serum 1-anti-
trypsin levels; overt dyslipidemia (fasting serum choles-
terol200 mg/dl or plasma triglyceride200 mg/dl) or
diabetes; exposure to occupational hepatotoxins or drugs
known to be steatogenic, hepatotoxic, or to affect lipid/
glucose metabolism. Mutations in the hemochromatosis
genes HFE and TRF2 were detected in patients and con-
trols using multiplex amplification reaction (Nuclear La-
ser Medicine, Milan, Italy). Part of the patients
participated in previous studies made in our Institution.9
All patients had a histological diagnosis of NASH, as
proposed by Brunt.13 Liver iron concentration and he-
patic iron index were determined from biopsies by atomic
absorption spectroscopy. The controls were 27 healthy
subjects comparable for age, sex, body mass index, waist
circumference, and waist-on-hip ratio with normal liver
enzymes (defined by ALT 30 U/l in men and 20 U/l
in women, based on the cutoff values provided by Prati et
al.,14 to enhance the negative predictive value of a normal
value) and abdomen ultrasound (Table 1).
Patients and controls gave their consent to the study,
which was conducted according to the Helsinki Declara-
tion.
Alimentary Record. Patients and controls filled in
daily a dietary record for 1 week, according to the EPIC
protocol, analyzed using the WinFood database (Medi-
matica, TE Teramo, Italy) as described.9
Anthropometry. Percent body fat was estimated by
the BIA method (TBF-202, Tanita, Tokyo, Japan),
closely correlating with dual X-ray absorptionmeasures.15
Cytokines. Serum tumor necrosis factor alpha, leptin,
and adiponectin were measured by sandwich enzyme-
linked immunosorbent assay (R&D System Europe Ltd,
Abingdon, UK). Resistin was measured by an enzyme
immunoassay (Bio Vendor Laboratory Medicine Inc.,
Brno, Czech Republic).
Oral Glucose Tolerance Test. After completion of
the alimentary record, patients and controls underwent a
standard 75-g oral glucose tolerance test. The whole-body
insulin sensitivity index (ISI) was calculated.16
Oral Fat Load. The 29 patients who had biopsies and
27 matched controls underwent an oral fat load test, as
previously described.17 Samples were drawn at 2-hour in-
tervals for 10 hours. Plasma total cholesterol (Chol), tri-
glyceride (Tg) and free fatty acids (FFA) were measured
by automated enzymatic methods. Apo E genotype was
determined by PCR amplification of genomicDNAusing
specific oligonucleotide primers. The 493 G/T MTP
gene polymorphism was assessed by PCR- restriction
fragment length polymorphism using a two-step nested
PCR.
Separation of Triglyceride-Rich Lipoprotein Sub-
fractions. Very-low-density lipoproteins (VLDL) were
isolated through preparative ultracentrifugation and sub-
sequently assayed for their Tg and total Chol content.
One aliquot plasma was brought to densities of 1,006 g/l
by adding a KBr solution (d 1,330 g/l) and centrifuged
at 105,000g for 21 hours at 10°C in a Beckman L8-70M
ultracentrifuge. Tg and total Chol concentration was then
determined in lipoprotein fraction enzymatically. The
first higher amount of blood (10 ml) was drawn for sub-
fractionating triglyceride-rich lipoprotein (TRLPs) by
ultracentrifugation on a discontinuous density gradient.
Separated plasmawas brought to a density of 1.10 g/ml by
adding solid KBr. The density gradient was prepared by
adding to 4 ml of this plasma 3 ml of a 1.065 g/ml solu-
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tion containing 0.05% KBr/NaCl plus EDTA (pH 7.4);
3 ml of a similar solution at 1.020 g/ml; 3 ml of physio-
logical saline at 1.006 g/ml. The sample was ultracentri-
fuged in a Beckman L8-70M centrifuge at 20°C in stages,
allowing the separation of four VLDL fractions with de-
creasing Sf values: A 400; B 175-400; C 100-175;
D 20-100. The first centrifugation (28,300 rpm for 43
minutes) isolated fraction A in a floating volume of 0.5
ml. The volume removed was replaced with physiological
saline, and the sample was centrifuged at 40,000 rpm for
67 minutes to isolate fraction B. This procedure was then
repeated at 40,000 rpm for 71minutes and at 37,000 rpm
for 18 hours to isolate fractions C and D, respectively.
The automated methods mentioned were used to deter-
mine Chol and Tg on the 4 fractions.
ApoB48 and ApoB100 Analysis. TRLP ApoB48 and
ApoB100 were separated by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) using 3.9%
gel. Nondelipidated samples were reduced in SDS buffer
for 4 minutes at 96°C. Samples were applied to the gel
Table 1. Baseline Characteristics of Controls and Patients With NASH According to -493 G/T MTP Polymorphism
Controls
GG (n  13)
Controls GT/TT
(n  14)
P
Controls
NASH-GG
(n  19)
NASH-GT/TT
(n  10) P NASH
Age (years) 35 2 37 2 0.890 39 2 37 3 0.597
Sex (M/F) 12/2 11/3 0.493 16/3 8/2 0.749
Smokers (%) 31 35 0.596 28 32 0.581
% Body fat 22 3 23 3 0.896 23 3 23 2 0.714
BMI (kg/m2) 25.0 0.7 25.1 0.8 0.947 24.9 0.5 25.6 0.9 0.533
Waist (cm) 88 2 90 2 0.750 90 2 91 3 0.681
WHR 0.91 0.02 0.92 0.03 0.697 0.93 0.02 0.92 0.01 0.593
Systolic BP (mmHg) 124 2 125 2 0.957 127 3 125 3 0.519
Diastolic BP (mmHg) 79 2 78 2 0.795 87 2‡§ 87 2‡§ 0.956
Triglycerides (mg/dl)* 62 5 79 6 0.041 78 7 104 9*† 0.034
Total C (mg/dl)† 173 7 181 8 0.496 182 10 179 9 0.187
HDL-C (mg/dl)† 61 1 59 1 0.897 45 1‡§ 50 2†§ 0.004
HDL2-C (mg/dl) 20 2 19 2 0.495 11 1‡§ 19 2§ 0.006
HDL3-C (mg/dl) 41 1 40 1 0.139 34 2‡§ 31 2‡§ 0.622
LDL-C (mg/dl)† 101 6 108 7 0.567 116 10 110 8 0.759
ApoB (mg/dl) 82 6 83 6 0.495 84 5 86 5 0.814
Glucose (mg/dl) 91 2 89 2 0.768 94 2 101 4 0.783
Insulin (U/mL) 4.2 1.5 3.8 1.4 0.586 13.5 2.2‡§ 12.6 1.6‡§ 0.814
Whole body ISI 8.01 0.81 7.38 0.62 0.549 4.59 0.78‡§ 3.52 0.81‡§ 0.284
AST (U/l) 24 3 19 2 0.697 46 4‡§ 38 4‡§ 0.231
ALT (U/l) 22 4 21 5 0.792 92 4‡§ 75 5‡§ 0.0258
GGT (U/l) 41 5 34 5 0.769 116 15‡§ 65 14‡§ 0.042
Total Br (mg/dl) 0.9 0.3 0.8 0.2 0.998 1.1 0.3 1.0 0.4 0.784
TNF- (pg/ml) 1.02 0.06 0.99 0.05 0.879 1.14 0.11 1.33 0.34 0.357
Adiponectin (ng/ml) 10591 670 11850 710 0.798 5088 575‡§ 5928 715‡§ 0.586
Leptin (pg/mL) 2178 823 2208 708 0.796 1605 211 1616 368 0.976
Resistin (ng/ml) 4.34 0.45 4.11 0.36 0.596 4.25 0.32 3.89 0.52 0.692
ApoE genotype
2-3 1 0 0.481 2 1 0.999
3-3 11 12 0.999 13 6 0.698
3-4 1 1 0.999 4 3 0.665
HFE mutation H63D heterozygotes (%) 16 8 0.159 18 20 0.892
Abdominal obesity (% subjects) 0 7 0.347 11 22 0.457
IGR (% subjects) 8 7 0.989 39*† 44*† 0.769
Hypertension (% subjects) 38 42 0.756 72† 55*† 0.478
Low HDL-C (%) 8 0 0.259 28*† 11† 0.964
High Tg (% subjects) 8 7 0.789 11 22*† 0.749
subjects with MS (%) 8 7 0.877 34*† 33*† 0.348
Steatosis (% hepatocyte) – – – 41 10 28 9 0.001
Necroinflammatory grade – – – 2.4 1.1 1.3 0.4 0.008
Fibrosis score – – – 2.5 1.2 1.1 0.5 0.003
NOTE. Data are presented as mean  SEM.
Abbreviations: BP, blood pressure; Br, bilirubin; ISI,insulin sensitivity index; total C, total cholesterol; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; WHR,
waist-on-hip ratio; Tg, triglyceride; IGR, impaired glucose regulation.
*P  0.05 versus controls GG.
†P  0.01 versus controls GT.
‡P  0.001 versus controls GG.
§P  0.001 versus controls GT/TT.
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and run at 40 mA in 0.025 M Tris, 0.192 M glycine, and
0.1% SDS. Gel was stained with Silver Stain (Bio-Rad).
Because the chromogenicity of ApoB48 is similar to that
of ApoB100, a protein standard was prepared from LDL
isolated by sequential ultracentrifugation and used to
quantify ApoB100 and ApoB48. The bands were quanti-
fied by densitometry using Gel Doc equipment (Bio-
Rad). Density values were assigned to the ApoB100 bands
of the standard LDL, and a standard curve was con-
structed. The values were recalculated by linear regres-
sion.
Markers of Lipid Peroxidation. LDL-conjugated
dienes were determined during the fat load test, as
follows. Capillary electrophoresis was performed as de-
scribed by Stocks and Miller.18 The cathode and anode
electrolytes and the capillary run buffer were 40 mM
methylglucamine-Tricine, pH 9.0. LDL samples were
injected by low pressure for 4 seconds. Dimethylform-
amide was injected as an electroendosmotic flow
marker for 1 second. A voltage of 24 kV was applied
ramping over 0.8 minutes. Migration of LDL particles
was monitored at 200 and 234 nm. The amount of
conjugated dienes was obtained from the percentage of
the height of LDL peak at 234 nm related to the height
of LDL peak at 200 nm.
Statistical Analysis. Data were expressed as mean 
SEM. .Differences were considered statistically significant
at P 0.05.Differences between groups were analyzed by
analysis of variance (ANOVA) when variables were nor-
mally distributed; otherwise the Mann-Whitney test was
used. Normality was evaluated by Shapiro-Wilk test. Chi-
square test or Fisher’s exact test were used to compare
categorical variables.
Data from the oral fat load were compared by ANOVA
and Scheffe` post hoc test after log normalization of
skewed variables. The area under the curve (AUC) and
incremental area under the curve AUC (IAUC) of plasma
Tg FFA and conjugated dienes during the oral fat load
were computed by the trapezoid method. Simple and
multiple regression analyses were used to estimate linear
relationship between different variables, after log transfor-
mation of skewed data. Logistic regression analysis was
used to identify independent predictors for VLDL
apoB48 and VLDL apoB100 subfraction responses. The
covariates were waist, ISI, MTP polymorphism, adi-
ponectin, and fasting insulin.
A logistic regression model was used to identify inde-
pendent predictors for severe steatosis, necroinflamma-
tory grade 3, or fibrosis stage 3. The covariates were age,
waist, ISI, MTP polymorphism, adiponectin, IAUC-tri-
glyceride/VLDL A apoB48/apoB100, IAUC-apoA1/
LDL conjugated dienes.
Results
Subject Characteristics. The main features of NASH
patients and controls grouped according to 493 MTP
genotype are shown in Table 1.
The prevalence of 493 MTP G/G carriers was 48%
in controls versus 66% in NASH (P 0.166), heterozy-
gous G/T carriers were 36% in controls versus 25% in
NASH (P  0.558), and homozygous TT carriers were
14% in controls versus 5% in NASH (P  0.665), as
described.11 There was no significant difference in Apo E
allelic frequency between the 4 groups. ISI, fasting insu-
lin, and adiponectin were significantly lower in patients
with NASH than in controls, but there was no difference
between NASH GG and NASH GT/TT (Table 1).
Plasma high-density lipoprotein-C (HDL-C) was
lower in NASH compared with controls, and homozy-
gous GG had lower HDL-C levels than NASH GT/TT
(Table 1). Plasma HDL2-C was similar in controls and
NASHGT/TT, whereas it was lower in NASHGG com-
pared with both NASH GT/TT and controls.
Four NASH GG and 2 NASH GT/TT had impaired
glucose tolerance on oral glucose tolerance test, 2 NASH
GG and 3 NASH GT/TT had had impaired fasting gly-
cemia (fasting plasma glucose  110 mg/dl but  126
mg/dl); the others had a normal glucose regulation (fast-
ing plasma glucose 110 mg/dl).
Adopting the ATP III criteria for definition of the met-
abolic syndrome,19 13 NASH GG and 5 NASH GT had
hypertension (systolic/diastolic blood pressure 130/85
mm Hg), 2 NASH GG and 2 NASH GT/TT were hy-
pertriglyceridemic (fasting plasma triglycerides 150
mg/dl), 5 NASH GG and 1 NASH GT/TT had low
plasma HDL-C (HDL-C  40 mg/dl in men and 50
mg/dl in women), 7 NASH GG and 4 NASH GT/TT
had impaired glucose regulation (either impaired fasting
glycemia, i.e., fasting plasma glucose 100 mg/dl but
126 mg/dl, or impaired glucose tolerance, i.e., plasma
glucose140 mg/dL at 2 hours on oral glucose tolerance
test), and 2NASHGGand 2NASHGT/TThad abdom-
inal obesity (waist circumference  102 cm in men and
88 cm in women). Thirty-four percent of NASH GG
and 33% of NASH GT/TT had the whole picture of the
metabolic syndrome (at least 3 criteria met).
Histopathology. Fatty infiltration was mild (involv-
ing 5%-33% of hepatocytes) in 9 patients, moderate
(33%-66% of hepatocytes) in 11 subjects, and severe
(66% of hepatocytes involved) in 9 patients. Necroin-
flammatory activity was grade 1 in 9 patients, grade 2 in 9,
and grade 3 in 11.
Fibrosis was stage 0 in 5 patients, 1 in 7 patients, 2 in 8
patients, and 3 in 9 patients; cirrhotic changes were absent
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(Table 1). Liver iron concentration was 15  3 mol/g
dry weight, and hepatic iron index was 0.50 0.04.
The severity of liver fatty infiltration, median necroin-
flammatory grade, and median fibrosis score were higher
in homozygous GG carriers than in GT/TT genotype
(Table 1).
Alimentary Record. Daily total energy and macro-
nutrient intake of patients with NASH and controls
were similar: total calories: 2,589  132 versus
2,476  145 kcal, P  0.875; carbohydrate: 50  2
versus 47  2% kcal, P  0.476; protein: 17  3
versus 20  2% kcal, P  0.568; fat: 33  2 versus
33  1% kcal, P  0.879. NASH group consumed
more saturated fat and less polyunsaturated fat than
controls, when expressed as both percentage of total
calories and percent total fat intake: saturated fatty
acids: 13.4  0.8 versus 9.2  0.5% tot kcal, P 
0.000; polyunsaturated fatty acids: 3.6  0.3 versus
5.2  0.4% tot kcal, P  0.000.
NASH patients also had a significantly lower daily in-
take of antioxidant vitamin A (568  176 vs. 1,078 
213 mg; P 0.008), vitamin C (105 12 vs. 156 10
mg; P 0.005) and E (5.7 0.4 vs. 9.8 0.4 mg, P
0.0002), as previously reported.17
Daily alcohol intake was similar in the two groups: 8
1 versus 9  2 g; P  0.458. No difference was seen in
daily antioxidant intake or in any other macro/micronu-
trient intake between genotypes GG and GT/TT in
NASH and controls (not shown).
Oral Fat Tolerance Test. Postprandial plasma total
Tg and FFA responses were significantly higher in the
NASH group than in controls, and homozygotes GG had
significantly higher Tg and FFA responses than their coun-
terpartGT/TT inbothNASHand controls (Fig 1;Table 2).
Fig. 1. Oral fat load test. Postprandial (A) plasma Tg, (B) FFA, (C) LDL conjugated dienes, (D) HDL-C, and (E) apoA1 responses in patients with
NASH and controls. Data are presented as mean  SEM. Star: P  0.05 versus controls GG. Circle: P  0.05 versus controls GT/TT. Rhombus:
P  0.05 NASH GG versus NASH-GT/TT. Triangle: P  0.05 controls GG versus controls GT/TT.
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Similarly, LDL conjugated diene response was higher
in patients with NASH than in controls, and homozy-
gotes GG had a significantly higher postprandial IAUC
LDL conjugated diene than GT/TT in both NASH and
control groups (Fig. 1; Table 2).
Fasting and postprandial HDL-C was lower in NASH
than in controls, and genotype GG had lower fasting and
postprandial HDL-C levels than genotype GT/TT in
both patients and controls. Fasting and postprandial
apoAI levels were lower in NASH than in controls, and
NASH GG had lower postprandial apoAI levels than
NASH GT/TT.
The postprandial response of smaller intestinal and he-
patic VLDL C and D was higher in GT/TT carriers than
in homozygous GG in both patients and controls, but
there was no difference in absolute values between NASH
and controls (Table 3; Fig 2). LDL-C, insulin, and glu-
cose levels did not change throughout the test (not
shown).
Correlative Analysis. Main correlations between an-
thropometric, metabolic, and dietary parameters in pa-
tients with NASH are shown in Table 4. IAUC Tg
correlated with adiponectin, ISI, fasting, and postprandial
HDL-C, IAUC LDL conjugated dienes, and with post-
prandial intestinal (r  0.65, P  0.0006), and hepatic
(r  0.43, P  0.026) VLDL A increase. On multiple
regression analysis, only basal adiponectin (  0.47;
P 0.009) and IAUC VLDL A apo B48 ( 0.48; P
0.008) predicted IAUC-Tg. IAUC FFA correlated with
postprandial intestinal and hepatic VLDL A increase,
HDL-C, and with LDL conjugated diene increase On
multiple regression analysis, only IAUCVLDLA apoB48
( 0.47; P 0.01) predicted IAUC FFA. IAUC LDL
conjugated dienes correlated with fasting adiponectin,
postprandial IAUC Tg, and FFA, with postprandial in-
testinal and hepatic VLDLA andD apoB48 and apoB100
increase, and with dietary intake of saturated fatty acid
and vitamin A (inversely). On multiple regression analy-
sis, only IAUC VLDL A apoB48 ( 0.52; P 0.002)
and vitamin A intake (  0.40; P  0.01) predicted
IAUC LDL conjugated dienes.
IAUC HDL-C correlated with IAUC Tg, IAUC
apoA1, IAUC FFA, IAUC VLDL A apoB48, and IAUC
VLDL A apoB100 on univariate analysis; on multiple
regression analysis, only IAUC VLDL A apoB48 (0.42;
P  0.009) independently predicted IAUC HDL-C.
Similarly, IACU apoA1 correlated with IAUC FFA( 
0.40; P 0.01) and IAUC VLDL A apoB48 ( 0.51;
P  0.003). On logistic regression analysis, MTP poly-
morphism (odds ratio [OR]  3.5; confidence interval
[CI] 1.8-5.8; P  0.0002), and adiponectin (OR  3.0;
CI 1.8-4.0; P  0.0008) predicted IAUC VLDL A
apoB48, IAUC VLDL A apoB100 (for MTP polymor-
phism: OR  2.8; CI 1.5-6.9; P  0.007; for adiponec-
tin: OR  3.1; CI 1.9-4.9; P  0.0006) and IAUC
VLDL B apoB48 (for MTP polymorphism: OR  2.0;
CI 1.4-4.9; P  0.005; for adiponectin: OR  2.1; CI
1.5-3.9; P  0.004).
MTP polymorphism predicted IAUC VLDL D
apoB48 (OR  2.8; CI 1.6-4.9; P  0.007) and IAUC
VLDL D apoB100 (OR  2.2; CI 1.4-3.8; P  0.009).
Similarly, VLDL C apoB48 and apoB100 responses were
independently predicted only by MTP polymorphism
(not shown). Hepatic steatosis was independently pre-
dicted by MTP polymorphism (OR 2.5; CI 1.8-7.9.4;
P  0.018), hypoadiponectinemia (OR  4.1; CI 1.6-
12.4; P  0.009), and IAUC VLDL A apoB48 (OR 
2.4; CI 1.7-9.6; P  0.031).
Table 2. Oral Fat Load Parameters of Patients With NASH and Controls According to -493 G/T MTP Polymorphism
Controls
GG
(n  13)
Controls
GT/TT
(n  14)
P
Controls
NASH-GG
(n  19)
NASH-GT/TT
(n  10) P NASH
Fasting Tg (mg/dl)* 62 5 79 6 0.041 78 7* 104 9*† 0.034
IAUC Tg (mg/dl  hr)* 179 33 85 31 0.038 552 79‡§ 277 64*§ 0.00001
Fasting FFA (mmol/l) 0.42 0.08 0.46 0.10 0.358 0.88 0.32‡§ 0.80 0.20‡§ 0.521
IAUC FFA (mmol/l  hr) 2.01 0.31 1.06 0.24 0.029 5.39 2.10‡§ 3.05 1.09‡§ 0.008
Fasting LDL C.D. (uA 234 nm/uA 200 nm  100 ) 6.38 1.41 6.07 1.02 0.365 6.92 1.43 8.18 2.08*† 0.129
IAUC LDL C.D. (uA 234 nm/uA 200 nm  100  hour) 1.9 0.5 0.4 0.2 0.015 25.2 5.1‡§ 5.7 3.9‡§ 0.00002
Fasting HDL-C (mg/dl) 61 1 59 1 0.897 45 1‡§ 50 2†§ 0.004
IAUC HDL-C (mg/dl  hour) 12 2 2 2 0.002 59 8‡§ 26 6‡§ 0.005
Fasting ApoA1(mg/dl) 122 4 127 5 0.694 106 4*† 112 4† 0.354
IAUC ApoA1 (mg/dl) 15 2 2 2 0.002 120 18‡§ 36 5‡§ 0.006
NOTE. Data are presented as mean  SEM.
Abbreviations: Tg, triglyceride; Glu, glucose; C, cholesterol; CD, conjugated dienes; adipo, adiponectin.
*P  0.05 versus controls GG.
†P  0.01 versus controls GT.
‡P  0.001 versus controls GG.
§P  0.001 versus controls GT/TT.
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Necroinflammatory grade 3 was predicted by fasting
adiponectin (OR  4.2; CI 1.5-16.0; P  0.008) and
IAUC-LDL coniugated dienes (OR  3.3; CI 1.4-9.7;
P 0.016). Stage 3 fibrosis was predicted by fasting adi-
ponectin (OR  5.0; CI 2.0-11.0; P  0.006), IAUC
apoA1 (OR  2.1; CI 1.5-4.0; P  0.015) and IAUC-
LDL conjugated dienes (OR  2.8; CI 1.0-8.5; P 
0.030).
Discussion
The main findings of our study are the following: (1)
despite comparable adiposity, insulin resistance and adi-
pokine profile, and lower fasting Tg levels, homozygous
MTP493 GG carriers of both NASH and controls had
a higher postprandial lipemia and LDL lipid peroxidation
and a more pronounced postprandial HDL-C and apoA1
fall than their counterpart genotype GT/TT; the magni-
tude of postprandial lipemia and lipid peroxidation pre-
dicted the severity of liver histology in NASH.
(2) The higher postprandial lipemia in GG homozy-
gosity was accounted for by a shift of circulating TRLPs
toward the larger, more Tg-rich subfractions. The large
TRLP subfractions response was related to MTP poly-
morphism and to adiponectin, whereas smaller TRLP re-
sponses are solely related to MTP polymorphism.
The association of493 G/T genotype with liver histol-
ogy in our patients confirms previous reports10:493MTP
GG homozygosity is more prevalent in NAFLD than in the
general population and has been considered a risk factor for
NAFLD; however, its role in the pathogenesis of fatty liver is
unclear.1,10 Although this study is not powered enough to
detect different prevalences in MTP genotypes between
groups, the absence of significant fatty liver in controls sug-
gests MTP GG polymorphism may not be per se sufficient
Table 3. Postprandial apoB Responses in VLDL Subfractions of Patients with NASH and Controls
Controls
GG
(n  13)
Controls
GT/TT
(n  14)
P
Controls
NASH-GG
(n  19)
NASH-GT/TT
(n  10)
P
NASH
Fasting VLDL A
ApoB48 (mg/dl)
0.33 0.18 0.12 0.10 0.010 1.33 0.64‡§ 0.62 0.23*§ 0.015
VLDL A IAUC
ApoB48 (mg/dl  hr)
1.07 1.04 0.47 0.23 0.008 4.66 1.21‡§ 2.07 1.00*† 0.0001
Fasting VLDL B
ApoB48 (mg/dl)
0.40 0.20 0.22 0.13 0.010 0.85 0.32‡§ 0.61 0.21*† 0.369
VLDL B IAUC
ApoB48 (mg/dl  hr)
0.78 0.17 0.32 0.13 0.009 3.48 1.02‡§ 1.43 0.21*† 0.0001
Fasting VLDL C
ApoB48 (mg/dl)
1.36 0.41 1.42 0.38 0.841 0.48 0.21‡§ 0.44 0.27‡§ 0.754
VLDL C IAUC
ApoB48 (mg/dl  hr)
2.79 1.38 5.51 1.04 0.001 2.91 1.07‡§ 5.69 1.43‡ 0.0001
Fasting VLDL D
ApoB48 (mg/dl)
1.89 0.35 2.49 0.35 0.007 0.74 0.38§ 1.48 0.47† 0.0001
VLDL D IAUC
ApoB48 (mg/dl  hr)
5.22 1.53 9.41 2.02 0.006 4.63 1.07‡§ 8.66 2.81* 0.0001
Fasting VLDL A
ApoB100 (mg/dl)
1.06 0.08 0.17 0.08 0.0001 4.38 0.85‡§ 2.39 1.21‡§ 0.0001
VLDL A IAUC
ApoB100 (mg/dl  hr)
2.68 1.25 1.26 0.84 0.009 13.73 2.65‡§ 6.58 1.53‡§ 0.001
Fasting VLDL B
ApoB100 (mg/dl)
1.40 0.36 0.71 0.12 0.010 2.33 1.19*† 1.21 0.38† 0.036
VLDL B IAUC
ApoB100 (mg/dl  hr)
5.21 1.17 2.42 0.86 0.0007 8.27 2.93‡ 5.27 1.16 0.002
Fasting VLDL C
ApoB100 (mg/dl)
4.87 1.49 5.25 1.51 0.219 0.69 0.25‡§ 3.33 1.11‡§ 0.0003
VLDL C IAUC
ApoB100 (mg/dl x hr)
3.96 1.14 6.80 2.01 0.007 4.01 1.79† 6.54 1.85* 0.003
Fasting VLDL D
ApoB100 (mg/dl)
6.70 1.26 9.21 1.57 0.003 1.47 0.85‡§ 5.07 1.19§ 0.0002
VLDL D IAUC
ApoB100 (mg/dl  hr)†
6.62 2.76 17.56 3.76 0.0004 5.58 2.18§ 18.81 4.19‡ 0.0002
NOTE. Data are given as mean  SEM.
*P  0.01 versus controls GG.
†P  0.01 versus controls GT.
‡P  0.001 versus controls GG.
§P  0.001 versus controls GT/TT.
HEPATOLOGY, Vol. 45, No. 5, 2007 GAMBINO ET AL. 1103
to cause NASH; rather, it is a modifier gene in NASH, sig-
nificantly impacting liver disease only when other “environ-
mental” factors (insulin resistance, hypoadiponectinemia,
reduced antioxidant intake) superimpose.
MTP polymorphism may affect NASH both directly,
by modulating MTP activity and consequent assembly
and secretion of hepatic VLDL,10 and indirectly, in a
more complex way, by affecting postprandial lipemia and
oxidative stress.9 Furthermore, the ability ofMTP to bind
stored Tg and facilitate their lipolysis and oxidation has
been recently hypothesized.20
The liver is an important scavenger of LDL and intes-
tinally derived remnants through the LDL- receptor and
the liver-related receptor protein; furthermore, hepatic
FFA uptake is driven exclusively by their plasma concen-
tration and contributes substantially to liver Tg pool in
NAFLD and diabetes.7,8 Our data link the postprandial
increase in TRLP and LDL dienes to the severity of liver
histology in NASH, suggesting that postprandial lipemia
may modulate oxidative liver injury in these subjects.
Consistently, oxidized LDL can bind to scavenger the
receptors CD36 of Kupffer and stellate cells, triggering
inflammatory cascade and extracellular matrix deposi-
tion21; the amount of oxidized LDL and the degree of
CD36 expression on activated stellate cells paralleled the
expression of the profibrotic cytokine transforming
growth factor beta and the severity of fibrosis in
NASH.22,23 Finally, an increased intracellular oxidative
stress experimentally impaired VLDL secretion and led to
Tg accumulation in hepatocytes, an effect totally reversed
by antioxidant treatment.24
The postprandial phase was suggested to be a major
atherogenic risk factor in diabetes.6 During this phase
TRLPs are hydrolyzed to remnants by lipases, LDL are
enrichedwith peroxidation-prone triglyceride, andHDLs
are depleted of cholesterol via cholesterol-ester transfer
protein. The proatherogenic effects of oxidized LDL and
TRLP-remnants on vascular endothelium and macro-
phages, as well as the protective role of HDL-C, are well
documented6: among metabolic syndrome components,
Fig. 2. Oral fat load test. Postprandial VLDL apoB48 (A-D) and apoB100 (E-H) subfraction responses in patients with NASH and controls. Data
are presented as mean  SEM. Star: P  0.05 versus controls GG. Circle: P  0.05 versus controls GT/TT. Rhombus: P  0.05 NASH GG versus
NASH-GT/TT. Triangle: P  0.05 controls GG versus controls GT/TT.
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in particular, low HDL-C predicted the highest cardio-
vascular risk.25 In our subjects, GG homozygosity dis-
played a higher postprandial Tg, FFA, and LDL
conjugated diene increase and a more pronounced de-
crease in circulating HDL-C and apoA1 than GT/TT
genotype counterpart despite comparable adiposity, insu-
lin resistance, adipokines, and lower fasting Tg levels. In
our subjects, excess of postprandial intestinal VLDL A
particles likely enhanced LDL lipid peroxidation and al-
tered the lipid composition of HDL particles, increasing
apoA1 catabolism and eventually lowering HDL-C lev-
els,26 as suggested by the independent correlation of post-
prandial VLDL A apo B48 with LDL conjugated dienes,
HDL-C, and apoA1 responses. The higher postprandial
lipemia, LDL lipid peroxidation, and the deeper post-
prandial HDL-C decrease of NASH GG compared with
NASHGT/TTmay confer on these patients an increased
cardiovascular risk, as recently reported in overweight
subjects,27 independently of classical risk factors, insulin
resistance, and metabolic syndrome,3-5 and provide a
pathogenetic mechanism for the inverse association be-
tween apoA1 levels and the severity of liver histology in
NASH.28
TRLP subfraction analysis disclosed that the higher
postprandial lipemia in homozygous GG versus GT/TT
genotypes is accounted for by the accumulation of larger,
more Tg-rich subfractions in both patients and controls.
The effect of this polymorphism on TRLP metabolism in
NAFLD has not been previously evaluated.
An elevated MTP activity has been linked to a higher
number of plasma smaller TRLP in diabetes in fasting
conditions.29-31Others found a higher number of fasting
circulating particles in both large and small TRLP sub-
fractions in GG versus TT genotype in healthy subjects.11
Another study in diabetic patients found a prevalence of
larger TRLP in MTP GG versus TT genotype postpran-
dially.32 Accordingly, in our subjects the postprandial li-
pemic response of GG carriers consists of larger TRLPs,
whereas smaller subfractions C and D account for the
lipemic response of GT/TT carriers in both patients and
controls.
Whether the accumulation of large TRLPs in GG ge-
notype is due to enhanced secretion or delayed clearance
cannot be elucidated without kinetic studies. Because ISI,
insulin, and adiponectin were similar in GG and GT/TT
genotypes and plasma insulin and glucose did not change
throughout the test (not shown) in both patients and
controls, differences in the inhibitory effect of insulin on
VLDL secretion are unlikely to contribute to the different
lipemic response of MTP GT genotypes.
Notably, obese MTP GG carriers showed a 35%
higher VLDL apoB100 secretion rate than the other ge-
notypes.33 Furthermore, hepatic Tg availability seems a
major determinant of large VLDL secretion rate in insulin
resistance.34,35 In the presence of liver fat accumulation by
different causes (defective FFA -oxidation, defective
VLDL secretion, increased FFA and Tg uptake), in-
creased Tg availability plus a reduced MTP activity may
Table 4. Pearson Correlation Coefficients Between Different Variables in Patients with NASH
HDL-C HDL2-C
IAUC
apoA1 ISI Adiponectin IAUC Tg IAUC FFA
IAUC LDL
C.D.
IAUC
VLDL A
apoB48
IAUC-Tg
IAUC
VLDL D
apoB48
IAUC VLDL
A
ApoB100
IAUC VLDL
D
ApoB100
IAUC
HDL-C Vit A SFA % E
HDL-C – 0.68‡ 0.21 0.50† 0.47* 0.42* 0.50* 0.12 0.45* 0.22 0.48* 0.22 0.11 0.35 0.20
HDL2-C 0.68‡ – 0.35 0.60‡ 0.48* 0.43* 0.45* 0.31 0.43* 0.18 0.53† 0.31 0.38 0.12 0.10
IAUC
apoA1
0.21 0.35 – 0.32 0.45* 0.40 0.61‡ 0.50† 0.63‡ 0.42* 0.21 0.60‡ 0.44* 0.28 0.31
ISI 0.50† 0.60‡ 0.32 – 0.59‡ 0.55‡ 0.39 0.32 0.38 0.45* 0.35 0.41 0.24 0.14 0.38
Adipo. 0.47* 0.48* 0.45* 0.59‡ – 0.74‡ 0.36 0.51‡ 0.65‡ 0.42* 0.60‡ 0.48* 0.26 0.13 0.35
IAUC-Tg 0.42* 0.43* 0.40 0.55‡ 0.74‡ – 0.39 0.72‡ 0.65‡ 0.32 0.43‡ 0.36 0.55‡ 0.14 0.31
IAUC FFA 0.50† 0.45 0.61‡ 0.39 0.36 0.39 – 0.55‡ 0.73‡ 0.32 0.43† 0.31 0.45* 0.26 0.23
IAUC
LDLC.D.
0.12 0.31 0.50† 0.32 0.51† 0.72‡ 0.55† – 0.58‡ 0.61‡ 0.42 0.50† 0.33 0.50† 0.64‡
IAUC VLDL A
apoB48
0.45* 0.43* 0.63‡ 0.38 0.65‡ 0.65‡ 0.73‡ 0.58‡ – 0.11 0.61‡ 0.22 0.68‡ 0.26 0.39
IAUC VLDL D
ApoB48
0.22 0.18 0.42* 0.45* 0.42* 0.32 0.32 0.61‡ 0.11 – 0.15 0.22 0.23 0.60‡ 0.18
IAUC VLDL A
ApoB100
0.48* 0.53† 0.21 0.35 0.60‡ 0.43* 0.43* 0.42 0.61‡ 0.15 – 0.33 0.42† 0.32 0.50†
IAUC VLDL D
ApoB100
0.22 0.31 0.60‡ 0.41 0.48* 0.34 0.31 0.50† 0.22 0.22 0.33 – 0.31 0.25 0.28
IAUC HDL-C 0.11 0.38 0.44* 0.24 0.26 0.55‡ 0.45* 0.33 0.68‡ 0.23 0.42* 0.31 – 0.20 0.15
vit A 0.35 0.12 0.28 0.14 0.13 0.14 0.26 0.50† 0.26 0.60‡ 0.32 0.25 0.20 – 0.24
SFA %E 0.20 0.10 0.31 0.38 0.35 0.31 0.23 0.64‡ 0.39 0.18 0.50† 0.28 0.15 0.24 –
NOTE. Statistically significant correlations are written in bold characters.
Abbreviations: Tg, triglyceride; Glu, glucose; C, cholesterol; C.D., conjugated dienes; adipo, adiponectin.
*P  0.05.
†P  0.01.
‡P  0.001.
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prolong the residence time of nascent TRLP in the cell,
allowing Tg enrichment of TRLPs; larger TRLPs finally
may accumulate in the circulation because of delayed
clearance; a higher MTP activity expedites secretion of a
larger number of small TRLPs, which are cleared more
quickly from the circulation.36 The postprandial accumu-
lation of large TRLP is magnified in a setting of higher
substrate (i.e., Tg, FFA) availability and defective TRLP
clearance such as the insulin-resistant state. The associa-
tion of hypoadiponectinemia with postprandial lipemia
and large TRLP responses is consistent with the ability of
this adipokine to enhance LPL-mediated TRLP catabo-
lism and FFA oxidation.1,37
These findings highlight the key role of Tg-rich li-
poprotein subfractions, beyond simple fasting lipid levels,
in determining postprandial metabolism and suggest the
combined impact of MTP activity and adipokines on li-
poprotein metabolism may be much more complex than
the picture that emerged from studies in fasting condi-
tions: despite lower fasting Tg levels, in fact, homozygous
GG carriers had a higher postprandial lipemia than the
GT/TT counterpart.
In conclusion, our study shows 493 GT MTP poly-
morphism significantly impacts liver disease and postpran-
dial lipid metabolism in NASH: for similar degrees of
adiposity, insulin resistance, adipokine profile, and similar
dietary habits, patients with GG homozygosity had more
severe liver disease and more atherogenic postprandial li-
poprotein profiles than the other genotypes. Postprandial
metabolism of large chylomicrons is a major determinant of
postprandial Tg, FFA, LDL, and HDL responses and may
have an important role in peroxidative liver injury and in
postprandial proatherogenic changes in NASH.
If the increased cardiovascular risk of homozygous GG
carriers with NAFLD is prospectively confirmed by larger
studies, assessing this MTP polymorphism may help se-
lect those subjects amenable to more aggressive, pharma-
cological intervention targeting postprandial lipid
metabolism (i.e., statins, PPAR-alpha agonists). Further-
more, our data suggest a reduced hepatic MTP function,
as obtained by MTP inhibitors, a novel class of hypoli-
pemic drugs currently under investigation, may be steato-
genic and convey highly atherogenic postprandial
lipoprotein changes.
Limitations of this study are its cross-sectional nature,
which prevents any causal inference, and the small num-
ber of subjects.
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